statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application...

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Mustang Bio stock climbs 9% amid drug development update...

Mustang Bio stock climbs 9% amid drug development update

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Mustang Bio announces vision for CAR T-Cell therapy platform expansion

Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the...

Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio files to sell common stock, warrants, no amount given

WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ( Mustang or the Company ) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical...

Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...

Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13R 2-targeted CAR T-Cells in High-Grade Glioma

WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ( Mustang or the Company ) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical...

Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Mustang Bio (MBIO Research Report), with a price target of $8.0...

BTIG Sticks to Its Buy Rating for Mustang Bio (MBIO)

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the translation of medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline includes CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors, and gene therapies for rare genetic disorders. The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Volume	167,934.00
52-Wk High	$8.17
52-Wk Low	$0.22

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.87	--	--	N/A
Q4'23	-$1.56	-$0.71	54.39%	BEAT
Q3'23	-$1.28	-$1.23	3.53%	BEAT
Q2'23	-$1.81	-$2.00	-10.65%	MISSED
Q1'23	-$3.01	-$2.06	31.56%	BEAT

MBIO Mustang Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals